ATE310000T1 - Ein thiazolidindionderivat und seine verwendung als antidiabetikum - Google Patents
Ein thiazolidindionderivat und seine verwendung als antidiabetikumInfo
- Publication number
- ATE310000T1 ATE310000T1 AT01963256T AT01963256T ATE310000T1 AT E310000 T1 ATE310000 T1 AT E310000T1 AT 01963256 T AT01963256 T AT 01963256T AT 01963256 T AT01963256 T AT 01963256T AT E310000 T1 ATE310000 T1 AT E310000T1
- Authority
- AT
- Austria
- Prior art keywords
- compound
- antidiabetic drug
- thiazolidinedione derivative
- thiazolidinedione
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0021784.4A GB0021784D0 (en) | 2000-09-05 | 2000-09-05 | Novel pharmaceutical |
| PCT/GB2001/003996 WO2002020520A1 (en) | 2000-09-05 | 2001-09-05 | A thiazolidinedione derivative and its use as antidiabetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE310000T1 true ATE310000T1 (de) | 2005-12-15 |
Family
ID=9898884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01963256T ATE310000T1 (de) | 2000-09-05 | 2001-09-05 | Ein thiazolidindionderivat und seine verwendung als antidiabetikum |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040044043A1 (de) |
| EP (1) | EP1315724B1 (de) |
| JP (1) | JP2004508370A (de) |
| KR (1) | KR100769008B1 (de) |
| CN (1) | CN1239501C (de) |
| AT (1) | ATE310000T1 (de) |
| AU (1) | AU2001284285A1 (de) |
| CY (1) | CY1105354T1 (de) |
| DE (1) | DE60115062T2 (de) |
| DK (1) | DK1315724T3 (de) |
| ES (1) | ES2248385T3 (de) |
| GB (1) | GB0021784D0 (de) |
| HK (1) | HK1057751A1 (de) |
| WO (1) | WO2002020520A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE39384E1 (en) | 1993-09-01 | 2006-11-07 | Smithkline Beecham P.L.C. | Substituted thiazolidinedione derivatives |
| ES2278977T3 (es) * | 2001-11-21 | 2007-08-16 | Smithkline Beecham Plc | Bencenosulfonato de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona; procedimiento para su preparacion; polimorfos i, ii y iii de los mismos; y su uso como ingrediente activo farmaceutico. |
| DE102005034406A1 (de) * | 2005-07-22 | 2007-02-01 | Ratiopharm Gmbh | Neue Salze von Rosiglitazon |
| US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| JP2009543805A (ja) * | 2006-07-13 | 2009-12-10 | スミスクライン ビーチャム コーポレーション | インドリン誘導体及びｇｐｒ１１９作動物質 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5741803A (en) * | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
| GB9726566D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB9726563D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB9726568D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel pharmaceutical |
-
2000
- 2000-09-05 GB GBGB0021784.4A patent/GB0021784D0/en not_active Ceased
-
2001
- 2001-09-05 AU AU2001284285A patent/AU2001284285A1/en not_active Abandoned
- 2001-09-05 DE DE60115062T patent/DE60115062T2/de not_active Expired - Fee Related
- 2001-09-05 JP JP2002525141A patent/JP2004508370A/ja not_active Withdrawn
- 2001-09-05 ES ES01963256T patent/ES2248385T3/es not_active Expired - Lifetime
- 2001-09-05 KR KR1020037003268A patent/KR100769008B1/ko not_active IP Right Cessation
- 2001-09-05 CN CNB018180264A patent/CN1239501C/zh not_active Expired - Fee Related
- 2001-09-05 EP EP01963256A patent/EP1315724B1/de not_active Expired - Lifetime
- 2001-09-05 US US10/363,456 patent/US20040044043A1/en not_active Abandoned
- 2001-09-05 WO PCT/GB2001/003996 patent/WO2002020520A1/en active IP Right Grant
- 2001-09-05 DK DK01963256T patent/DK1315724T3/da active
- 2001-09-05 AT AT01963256T patent/ATE310000T1/de not_active IP Right Cessation
-
2003
- 2003-11-25 HK HK03108591A patent/HK1057751A1/xx not_active IP Right Cessation
-
2006
- 2006-01-23 CY CY20061100083T patent/CY1105354T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1105354T1 (el) | 2010-03-03 |
| GB0021784D0 (en) | 2000-10-18 |
| EP1315724A1 (de) | 2003-06-04 |
| KR100769008B1 (ko) | 2007-10-22 |
| KR20030027112A (ko) | 2003-04-03 |
| CN1471529A (zh) | 2004-01-28 |
| DE60115062T2 (de) | 2006-06-29 |
| EP1315724B1 (de) | 2005-11-16 |
| ES2248385T3 (es) | 2006-03-16 |
| HK1057751A1 (en) | 2004-04-16 |
| WO2002020520A1 (en) | 2002-03-14 |
| AU2001284285A1 (en) | 2002-03-22 |
| CN1239501C (zh) | 2006-02-01 |
| DK1315724T3 (da) | 2006-02-20 |
| US20040044043A1 (en) | 2004-03-04 |
| DE60115062D1 (de) | 2005-12-22 |
| JP2004508370A (ja) | 2004-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105354T1 (el) | Ένα παραγωγο θειαζολιδινοδιονης και η χρηση του σαν αντι-διαβητικο | |
| ATE343574T1 (de) | Ein thiazolidindionderivat und seine verwendung als antidiabetikum | |
| NZ515166A (en) | Thiazolidinedione derivative and its use as antidiabetic | |
| AP1814A (en) | Tartrate salts of thiazolidinedione derivative. | |
| DK1349855T3 (da) | 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dionmesylatsalt | |
| ATE329914T1 (de) | Rosiglitazon-edisylate und ihre verwendung als antidiabetika | |
| AP1715A (en) | The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione | |
| AP1680A (en) | Thiazolidinedione derivative and its use as antidiabetic. | |
| MXPA02012100A (es) | Sal de tiazodilindiona para el tratamiento de la diabetes mellitus. | |
| AP1785A (en) | Tartrate salt of thiazolidinedione derivative. | |
| AP2002002684A0 (en) | 5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2- pyridyl) amino)ethoxy) benzyl) thiazolidine-2, 4-dione hydriodide as pharmaceutical.5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy)benzyl) thiazolidine-2,4-dione hydriodide as pharmaceutical | |
| CY1107767T1 (el) | Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο | |
| HK1068884A1 (en) | 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyleof; and its use as pharmaceutical active ingredie)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thernt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1315724 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |